contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nomination-committee-appointed-ahead-of-agm-2026-in-synact-pharma-ab

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

SynAct Pharma

SynAct Pharma AB (publ) (”SynAct”) today announced that the Nomination Committee in preparation for the Annual General Meeting (AGM) 2026 on June 11, has been appointed.Pursuant to the instruction...

<div class="mfn-preamble"><p><strong>SynAct Pharma AB (publ) (”SynAct”) today announced that the Nomination Committee in preparation for the Annual General Meeting (AGM) 2026 on June 11, has been appointed.</strong></p></div><div class="mfn-body"><p>Pursuant to the instruction and charter for the Nomination Committee adopted at the AGM held on May 28, 2024, the Nomination Committee shall consist of four members, representing the three largest shareholders as per end of September, together with the chairman of the Board of Directors.</p><p>Based on the above, the Nomination Committee for the AGM 2026 has been established to consist of the following persons:</p><ul><li>Mark Gandrup, appointed by Sanos ApS</li><li>Thomas Ringberg</li><li>Niels Ankerstjerne Sloth appointed by TJ Biotech ApS</li><li>Anders Kronborg, Chairman of the Board</li></ul><p>In total, the Nomination Committee represents more than 20% of the total number of shares and votes in the company as of September 30, 2025.<br><br>The task of the Nomination Committee is to prepare and present proposals to the AGM regarding the Chairman of the AGM, the election of the Chairman and other members of the Board of Directors, the remuneration of the Board of Directors divided between the Chairman and the other members, any remuneration for Committee work and the election and remuneration of the auditor. Finally, the Nomination Committee will propose principles for the appointment of the Nomination Committee (if the Nomination Committee considers that the<br>current principles and instructions should be updated).</p><p>Shareholders are welcome to submit their proposals and views to the Nomination Committee to SynAct Pharma AB, Att: Nomination Committee, c/o SynAct Pharma, Medicon Village, Scheelevägen 2, 223 63 Lund, or by e-mail to <a rel="noopener" href="mailto:valberedning@synactpharma.com">valberedning@synactpharma.com</a>. <br><br>To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than January 31, 2026.</p><p>The Nomination Committee's proposals will be announced in the notice for the AGM 2025 and on SynAct’s web site.</p></div><div class="mfn-footer mfn-contacts mfn-f17dbb204e96"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Jeppe Øvlesen<br>CEO, SynAct Pharma AB<br>Phone: + 45 2844 7567<br>E-mail: investor.relations@synactpharma.com</p></div><div class="mfn-footer mfn-about mfn-fae3b067917e"><p><strong class="mfn-heading-1">About SynAct Pharma AB</strong><br>SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information:&nbsp;<a rel="noopener" href="https://synactpharma.com/">https://synactpharma.com/</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/a7994f0a-0579-46ad-add7-97a837d1319b/nomination-committee-appointed-ahead-of-agm-2026-in-synact-pharma-ab.pdf" class="mfn-generated mfn-primary">Nomination committee appointed ahead of AGM 2026 in SynAct Pharma AB</a></p></div>